Stockreport

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

BAYER AG S/ADR  (BAYRY) 
NASDAQ:AMEX Investor Relations: investor.bayer.com
PDF Not intended for UK MediaOCEANIC-STROKE demonstrates superiority of asundexian with antiplatelet therapy, showing significant reduction in ischemic stroke risk, without [Read more]